GHRP-2
Also known as: Growth Hormone Releasing Peptide-2
Synthetic ghrelin mimetic that stimulates GH release with moderate appetite stimulation.
Evidence
Moderate
FDA status
Not FDA-approved
Source
Synthetic hexapeptide ghrelin mimetic
Overview
Synthetic ghrelin mimetic that stimulates GH release with moderate appetite stimulation.
Mechanism of Action
Binds ghrelin receptor (GHS-R1a) to trigger GH release, moderate cortisol and prolactin elevation, increases appetite via ghrelin pathway, studied alongside GHRH analogs.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- GH release
- Increases IGF-1
- Muscle mass
- Improved recovery
- Better sleep quality
- Appetite
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. GHRP-2 isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Clinical trials, preclinical research
Clinical evidence for GH stimulation. Less selective than ipamorelin (affects cortisol/prolactin). Raises GH; long-term safety data are lacking.
Safety Information
Potential Side Effects
- •Increased hunger
- •Water retention
- •Numbness/tingling
- •Mild cortisol elevation
Contraindications
- Active cancer
- Pregnancy
- Breastfeeding
Interactions
- ⚠Synergistic with CJC-1295 or GHRH
Quick Facts
Related Peptides
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.
Ipamorelin
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.